I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

Investigational Compounds

We are dedicated to delivering first-in-class cancer cell directed therapies and boldly pursuing innovative strategies in immuno-oncology. We are also designing smart combinations with the goal of bringing benefit to patients. Find out more about how we’re taking cancer on through our oncology clinical trial programme.

Explore the videos and materials below to learn more about how Boehringer Ingelheim are taking cancer on.

Video
Discover how our R&D programmes are aiming to develop exceptional medicines for cancer patients
Discover how our R&D programmes are aiming to develop exceptional medicines for cancer patients
Video
Norbert Kraut outlines our leading programme of cancer cell-directed research approaches
Norbert Kraut outlines our leading programme of cancer cell-directed research approaches
Video
Jonathon Sedgwick discusses our long-term commitment to immuno-oncology research
Jonathon Sedgwick discusses our long-term commitment to immuno-oncology research
Video
Explore our immuno-oncology research strategies to target cold tumours with Jonathon Sedgwick
Explore our immuno-oncology research strategies to target cold tumours with Jonathon Sedgwick

Did you find this information useful?

Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063 and BI 1361849 are investigational compounds and have not been approved. Their safety and efficacy have not been established.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: May 2019